Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2.
Abida W, Bryce A, Vogelzang N, Amato R, Percent I, Shapiro J, McDermott R, Hussain A, Patnaik A, Petrylak D, Ryan C, Stanton T, Zhang J, Loehr A, Simmons A, Despain D, Golsorkhi A, Watkins S, Scher H, Chowdhury S. Genomic characteristics of deleterious BRCA1 and BRCA2 alterations and associations with baseline clinical factors in patients with metastatic castration-resistant prostate cancer (mCRPC) enrolled in TRITON2. Journal Of Clinical Oncology 2019, 37: 5031-5031. DOI: 10.1200/jco.2019.37.15_suppl.5031.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerBaseline clinical characteristicsDNA damage repair genesClinical characteristicsBRCA1 patientsProstate-specific antigen levelCastration-resistant prostate cancerBaseline clinical factorsMeasurable tumor burdenDeleterious alterationsGenomic alterationsCo-occurring alterationsRepair genesNext-generation sequencing assayBRCA alterationsMCRPC patientsBaseline PSAPSA levelsClinical factorsTumor burdenDeleterious germlineAntigen levelsBRCA mutationsBRCA2 alterationsDeleterious BRCA1